Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression
Open accessThe DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Abstract
Abstract Molecular events activating the PI3K pathway are frequently detected in human tumors and the activation of PI3K signaling alters numerous cellular processes including tumor cell proliferation, survival, and motility. More recent studies have highlighted the impact of PI3K signaling on the cellular response to interferons and other immunologic processes relevant to antitumor immunity. Given the ability of IFNγ to regulate antigen processing and presentation and the pivotal role of MHC class I (MHCI) and II (MHCII) expression in T-cell–mediated antitumor immunity, we sought to determine the impact of PI3K signaling on MHCI and MHCII induction by IFNγ. We found that the induction of cell surface MHCI and MHCII molecules by IFNγ is enhanced by the clinical grade PI3K inhibitors dactolisib and pictilisib. We also found that PI3K inhibition increases STAT1 protein levels following IFNγ treatment and increases accessibility at genomic STAT1-binding motifs. Conversely, we found that pharmacologic activation of PI3K signaling can repress the induction of MHCI and MHCII molecules by IFNγ, and likewise, the loss of PTEN attenuates the induction of MHCI, MHCII, and STAT1 by IFNγ. Consistent with these in vitro studies, we found that within human head and neck squamous cell carcinomas, intratumoral regions with high phospho-AKT IHC staining had reduced MHCI IHC staining. Implications: Collectively, these findings demonstrate that MHC expression can be modulated by PI3K signaling and suggest that activation of PI3K signaling may promote immune escape via effects on antigen presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K and AKT1 inhibitors have also been shown to boost IFNG-driven class I and class II antigen presentation as a mechanism of cancer-cell-dependent immunostimulation (Chandrasekaran et al., 2019; Marijt et al., 2019; Sivaram et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chandrasekaran et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · cited 1×
“Enriched accessible loci were identified byMACS2anddifferentially accessible regions (DAR)determined between sample groups with edgeR (15, 16).”
BackgroundUltrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849 · cited 1×
“the hg19 version of the human genome using Bowtie with the default parameters (14).”
MethodModel-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386 · cited 1×
“Enriched accessible loci were identified byMACS2anddifferentially accessible regions (DAR)determined between sample groups with edgeR (15, 16).”
BackgroundCerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339 · cited 1×
“To this end, we assessed how the loss of PTEN expression would influence MHCI and MHCII induction by IFNg using commercially available parental HCT116 colon carcinoma cells and HCT116 cells that were rendered PTEN null by CRISPR/Cas9 gene editing (41).”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382 · cited 1×
“STAT1 motifs in DAR were identified using HOMER (17).”
MethodBuenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.
Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A., & Fusenig, N. E. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.3.761 · Cited by 4,170
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Research works printed but not linked: 1
- Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, Iliopoulos D, van den Elsen PJ, Kobayashi KS. 2010 NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci U S A 107: 13794– 9 20639463 PMC2922274
Cited by
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
“Activation of the PI3K pathway attenuates the expression of MHC class I and II expression, while inhibition of this pathway reverses the suppression of antigen presentation machinery via interferon γ [105].”
BackgroundPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“A similar result has been found in human head and neck squamous cell carcinomas [72].”
ResultImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Metadata
- Authors
- Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., Lesinski, G. B., Waller, E. K., Thomas, S. N., Kotenko, S. V., Boss, J. M., Moreno, C. S., Swerlick, R. A., & Pollack, B. P.
- Affiliations
- Emory University (US)
- Atlanta VA Medical Center (US)
- University of Pennsylvania (US)
- Georgia Institute of Technology (US)
- Rutgers New Jersey Medical School (US)
- Corresponding author
- Pollack, Brian P.
- ORCID
- Venue
- Molecular Cancer Research
- Published
- 2019-12-01
- Volume
- 17
- Issue
- 12
- Pages
- 2395-2409
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC7339488
- OpenAlex
- W2976327003
- Cited by
- 61
- References
- 70
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 12 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 3
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (1I01BX001922-01A1)
- Office of Extramural Research, National Institutes of Health (5P50CA128613-05, 5R01CA207619-03, T32CA160040, P30CA138292, UL1TR002378)
- Winship Cancer Institite (Skin cancer and melanona fund)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- phosphoinositide 3-kinase signaling, MHC class I expression, MHC class II expression, interferon-gamma, STAT1, PI3K inhibitors, dactolisib, pictilisib, PTEN, antigen processing and presentation, antitumor immunity, immune evasion, head and neck squamous cell carcinoma, Akt phosphorylation
- MeSH terms
- Squamous Cell Carcinoma of Head and Neck, Binding Sites, DNA-Binding Proteins, Genes, MHC Class II, Genes, MHC Class I, Humans, Interferon-gamma, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Antigen Presentation, Genomics, Protein Kinase Inhibitors, Cell Proliferation, STAT1 Transcription Factor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Phosphatidylinositol 3-Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-19-0545
- The paper
- Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., Lesinski, G. B., Waller, E. K., Thomas, S. N., Kotenko, S. V., Boss, J. M., Moreno, C. S., Swerlick, R. A., & Pollack, B. P. (2019). Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-19-0545
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.